ArticleJournal of cancer research and clinical oncology2015
Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study.
Article in Journal of cancer research and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Diffuse large B‑cell lymphoma followed by myelodysplastic syndrome with TP53 mutation: a case report and literature review.Frontiers in oncology · 2026Article
- Stereotactic body radiation therapy for hepatocellular carcinoma: a comprehensive review.Frontiers in oncology · 2026Review
- The risk and distribution of second primary cancers according to subsite of primary stomach cancer: a retrospective cohort population-based study.Annals of medicine and surgery (2012) · 2024Article
- Risk of second primary cancers in nodal non-Hodgkin lymphoma patients by primary lymph node location: a retrospective cohort population-based study.Annals of medicine and surgery (2012) · 2024Article
- A case of concurrent follicular lymphoma and lung cancer requiring differentiation from lymph node metastasis.Thoracic cancer · 2024Article
- Lifetime risks of second primary malignancies after pediatric Hodgkin lymphoma and non-Hodgkin lymphoma.Journal of cancer research and clinical oncology · 2024Article
- Risk and prognosis of secondary breast cancer after radiation therapy for non-Hodgkin lymphoma: a massive population-based analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Synchronous mantle cell lymphoma bone marrow involvement complicated with extensive-stage small cell lung cancer: A case report and literature review.Oncology letters · 2022Article
- Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study.Blood advances · 2022Article
- Second primary malignancies after ocular adnexal lymphoma diagnosis.BMC ophthalmology · 2021Article
- Article
- Prognosis of Hepatocellular Carcinoma Among Cancer Survivors with Other Types of Primary Tumors.Digestive diseases and sciences · 2020Article
- Compliance with cancer screening and influenza vaccination guidelines in non-Hodgkin lymphoma survivors.Journal of cancer survivorship : research and practice · 2020Article
- Second primary malignancies among cancer patients.Annals of translational medicine · 2020Article
- Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab.Blood advances · 2019Article
- Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes.Blood advances · 2019Article
- Secondary mixed phenotype acute leukemia following chemotherapy for diffuse large B-cell lymphoma: a case report and review of the literature.International journal of clinical and experimental pathology · 2018Article
- Synchronous Hodgkin lymphoma and gastric adenocarcinoma: A rare case report and literature review.Medicine · 2018Review
- Hepatitis C virus - associated B cell non-Hodgkin's lymphoma.World journal of gastroenterology · 2016Review
- Lack of efficacy of imiquimod in patients with basal cell carcinoma previously treated with rituximab for B cell lymphoma: two case reports.Journal of medical case reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundWith the improved survival of non-Hodgkin lymphoma (NHL) patients, development of second primary malignancy (SPM) has become an increasingly important issue in these long-term survivors.
methodsWe conducted a retrospective study to analyze NHL patients diagnosed between January 1997 and December 2010 in Taiwan. Standardized incidence ratios (SIRs) were applied to compare the risk of SPMs in NHL patients and the general population. Multivariate analysis was performed to determine the independent predictors of SPM.
resultNHL patients have a significantly greater risk of developing SPM [SIR 1.43; 95 % confidence interval (CI) 1.32-1.55; p < 0.001). A significantly high SIR was noted for leukemia, myeloma, and neoplasms of the bone and soft tissue, thyroid, central nervous system, skin, stomach, head and neck, liver and biliary tract, and the lungs and mediastinum. Multivariate analysis revealed that age ≥60 years [hazard ratios (HR) 2.04], being male (HR 1.22), comorbidities of chronic obstructive pulmonary disease (HR 1.34), liver cirrhosis (HR 1.50), hepatitis C infection (HR 1.94) and therapy containing radiotherapy (HR 1.38) were the significant predictors for SPM occurrence. The median follow-up time and survival time were 3.37 and 9.45 years, respectively.
conclusionThis Taiwanese population-based study provides updated data about the risk of SPM in NHL patients, demonstrating an approximately 1.5 time greater risk of SPM compared to the general population. A high risk of SPM for myeloma and hepatocellular carcinoma is unique to Asian patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.